DEVA "Doktor, Eczacı ve Alatları" (Physicians, Pharmacists and Diagnostics) Sanayi ve Ticaret A.Ş. was incorporated.

Bomonti pharmaceutical plant was opened.

The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey. The title and status of the Company was changed from DEVA "Doktorlar Ecza ve Alat" (Physicians Drugs and Equipment) Sanayi ve Ticaret Anonim Şirketi to DEVA Holding A.Ş.

Carlo Erba pharmaceutical plant was purchased.

A detergent and cologne factory was set up in İzmit.

The shares of DEVA Holding started to be traded on the Istanbul Stock Exchange.

The foundation of the synthesis plant were laid in Çerkezköy.

The capital of DEVA Holding A.Ş. was increased to TL 4 trillion and the number of shareholders reached 15,000.

The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.

50 years of success in the sector was celebrated together with doctors and pharmacists all around Turkey.

• DEVA signed the AP Contract on Nov 30, 2010 for the takeover of Production Facility at Çerkezköy Organized Ind. Zone – Tekirdağ owned by Zentiva, engaged in manufacturing drug substance with an area of 67.551 m2 with closed area of 18.742 m2 with royalty for manufacture, sales and export of some drug substances manufactured at said Production Facility and 61 personnel working at aforementioned plant together with entire machinery and equipment including all rights.
• Transactions as to merger of DEVA Holding with DEVA İlaç Sanayi ve Ticaret A.Ş. by takeover was completed as of December 31, 2010. Due to such merger, its issued capital was increased from 180.000.000 TL to 180.070.656 TL within its registered authorized stock and the entire amount was given to partners of DEVA İlaç Sanayi ve Ticaret A.Ş. apart from DEVA Holding. This merger served the purpose of reaching a more efficient business model and of operational cost saving.
• Turkey’s leading drug manufacturer DEVA Holding delivered drug aid package of 412.3 thousand Turkish Liras composed of 31 palettes to Save the Children Germany Organization. Drug aid package to be used to heal the wounds of flood victims and composed of 62.6 thousand of DEVA drugs shall be conveyed by Save The Children Organization to those in need.
• DEVA Holding, the leading drug manufacturer in Turkey, delivered its aid package consisting of 1.581 parcels of medicine worth a total of 2.4 million Turkish Liras to the Turkish Red Crescent Society in October and 1.355 parcels to be used to heal the wounds of Pakistan’s flood victims and containing DEVA pharmaceuticals will be distributed to those in need by the Turkish Red Crescent Society. Moreover, it supported Turkish Red Crescent through blood donation over 120 units.
• In 2010, DEVA Holding joins with DEVA İlaç Sanayi ve Ticaret A.Ş.

• 2013 Registered supplier of UN. DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.

• DEVA was selected as the Best R&D Company by the Turkish Ministry of Science, Technology and Industry.
• DEVA, was selected as the Best R&D Company by Eczacı Magazine.

• In 2018, Turkey’s largest pharmaceutical logistics center, started its operations with 32.000 pallet capacity.
• Devatis US accelerated it’s operations.
• Devatis Switzerland has passed Swissmedic inspection.

• Our product registration approvals are more than 800 in more than 60 countries.

• Our marketing authorizations reached 1029 in 69 countries.